Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis

Journal of Immunology

Volumn 174, Issue 1, 2005, Pages 41-50

  Hill, Seran C ^a   Youde, Sarah J ^c   Man, Stephen ^c   Teale, Glyn R ^a,b   Baxendale, Amanda J ^a   Hislop, Andrew ^a   Davies, Clare C ^a   Luesley, David M ^b   Blom, Anna M ^d   Rickinson, Alan B ^a   Young, Lawrence S ^a   Eliopoulos, Aristides G ^a,e  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; BINDING PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CELL SURFACE MARKER; EPITOPE; ETOPOSIDE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; QUERCETIN;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL LINE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSLATION INITIATION; TUMOR CELL; UPREGULATION; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 19944419103     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.1.41     Document Type: Article

References (57)

1. van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukocyte Biol. 67:2.
2. Callard, R. E., R. J. Armitage, W. C. Fanslow, and M. K. Spriggs. 1993. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14:559.
3. Hayward, A. R., J. Levy, F. Facchetti, L. Notarangelo, H. D. Ochs, A. Etzioni, J.-Y. Bonnefoy, M. Cosyns, and A. Weinberg. 1997. Cholangiopathy and tumours of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 158:977.
4. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, and H. Kikutani. 1994. The immune responses in CD40 deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167.
5. Xu, J., T. M. Foy, J. D. Laman, E. A. Elliot, J. J. Dun, T. J. Waldscmidt, J. Elsemore, R. J. Noelle, and R. A. Flavell. 1994. Mice deficient for the CD40 ligand. Immunity 1:423.
6. Funakoshi, S., D. L. Longo, M. Beckwith, D. K. Conley, G. Tsarfaty, I. Tsarfaty, R. J. Armitage, W. C. Fanslow, M. K. Spriggs, and W. J. Murphy. 1994. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83:2787.
7. Baker, M. P., A. G. Eliopoulos, L. S. Young, R. J. Armitage, C. D. Gregory, and J. Gordon. 1998. Prolonged phenotypic, functional and molecular changes in group I Burkitt lymphoma cells on short term exposure to CD40 ligand. Blood 92:2830.
8. Henriquez, N. V., E. Floettmann, M. Salmon, M. Rowe, and A. B. Rickinson, 1999. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. J. Immunol. 162:3298.
9. Eliopoulos, A. G., C. W. Dawson, G. Mosialos, J. E. Floettmann, M. Rowe, R. J. Armitage, J. Dawson, J. M. Zapata, D. J. Kerr, M. J. O. Wakelam, et al. 1996. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13:2243.
10. Hirano, A., D. L. Longo, D. D. Taub, D. K. Ferris, L. S. Young, A. G. Eliopoulos, A. Agathanggelou, N. Cullen, J. Macartney, W. C. Fanslow, and W. J. Murphy. 1999. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93:2999.
11. Tong, A. W., M. H. Papayoti, G. Netto, D. T. Armstrong, G. Ordonez, J. M. Lawson, and M. J. Stone. 2001. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin. Cancer Res. 7:691.
12. Young, L. S., C. W. Dawson, K. W. Brown, and A. B. Rickinson. 1989. Identification of a human epithelial cell surface protein sharing an epitope with C3d/ Epstein-Barr virus receptor molecule of B lymphocytes. Int. J. Cancer 43:786.
13. Gallagher, N. J., A. G. Eliopoulos, A. Agathangelo, J. Oates, J. Crocker, and L. S. Young. 2002. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol. Pathol. 55:110.
14. Cooke, P. W., N. D. James, R. Ganesan, M. Wallace, A. Burton, and L. S. Young. 1999. CD40 expression in bladder cancer. J. Pathol. 188:38.
15. Afford, S. C., S. Randhawa, A. G. Eliopoulos, S. G. Hubscher, L. S. Young, and D. H. Adams. 1999. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J. Exp. Med. 189:441.
16. Davies, C. C., J. Mason, M. J. Wakelam, L. S. Young, and A. G. Eliopoulos. 2004. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J. Biol. Chem. 279:1010.
17. Khanna, R., L. Cooper, N. Kienzle, D. J. Moss, S. R. Burrows, and K. K. Khanna. 1997. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkill's lymphoma cells. J. Immunol. 159:5782.
18. Kato, K., M. J. Cantwell, S. Sharma, and T. J. Kipps. 1998. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest. 101:1133.
19. Wierda, W. G., M. J. Cantwell, S. J. Woods, L. Z. Rassenti, C. E. Prussak, and T. J. Kipps. 2000. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96:2917.
20. French, R. R., H. T. C. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T cell help. Nat. Med. 5:548.
21. Mackey, M. F., J. R. Gunn, C. Maliszewski, H. Kikutani, R. J. Noelle, and R. J. Barth. 1998. Dendritic cells require maturation via CD40 to generate protective anti-tumour immunity. J. Immunol. 161:2094.
22. Kikuchi, T., and R. G. Crystal. 1999. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum. Gene Ther. 10:1375.
23. Eliopoulos, A. G., M. Stack, C. W. Dawson, K. M. Kaye, L. Hodgkin, S. Sihota, M. Rowe, and L. S. Young. 1997. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 14:2899.
24. + T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J. Exp. Med. 194:1053.
25. Evans, M., L. K. Borysiewicz, A. S. Evans, M. Rowe, M. Jones, U. Gileadi, V. Cerundolo, and S. Man. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167:5420.
26. Boursnell, M. E., E. Rutherford, J. K. Hickling, E. A. Rollinson, A. J. Munro, N. Rolley, C. S. McLean, L. K. Borysiewicz, K. Vousden, and S. C. Inglis. 1996. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14:1485.
27. Eliopoulos, A. G., C. C. Wang, C. D. Dumitru, and P. N. Tsichlis. 2003. Tp12 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 22:3855.
28. Steven, N. M., A. M. Leese, N. E. Annels, S. P. Lee, and A. B. Rickinson. 1996. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med. 184:1801.
29. Lautscham, G., A. Rickinson, and N. Blake. 2003. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus. Microbes Infect. 5:291.
30. Hess, S., and H. Engelmann. 1996. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. 183:159.
31. Eliopoulos, A. G., C. Davies, P. G. Knox, N. J. Gallagher, S. C. Afford, D. H. Adams, and L. S. Young. 2000. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol. Cell. Biol. 20:5503.
32. Scherf, U., D. T. Ross, M. Waltham, L. H. Smith, J. K. Lee, L. Tanabe, K. W. Kohn, W. C. Reinhold, T. G. Myers, D. T. Andrews, et al. 2000. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24:236.
33. Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem. 269:5241.
34. Walker, E. H., M. E. Pacold, O. Perisic, L. Stephens, P. T. Hawkins, M. P. Wymann, and R. L. Williams. 2000. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6:909.
35. Davies, S. P., H. Reddy, M. Caivano, and P. Cohen. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:95.
36. Ferry, D. R., A. Smith, J. Malkhandi, D. W. Fyfe, P. G. deTakats, D. Anderson, J. Baker, and D. J. Kerr. 1996. Phase 1 clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase activity. Clin. Cancer Res. 2:659.
37. Tee, A. R., and C. G. Proud. 2000. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 19:3021.
38. Gingras, A. C., B. Raught, and N. Sonenberg. 2001. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15:807.
39. Costello, R. T., J.-A. Gastaut, and D. Olive. 1999. What is the real role of CD40 in cancer immunotherapy? Immunol. Today 20:488.
40. Schultze, J., and P. Johnson. 1999. A stimulating new target for cancer immunotherapy. Lancet 354:1225.
41. Tutt, A. L., L. O'Brien, A. Hussain, G. R. Crowther, R. R. French, and M. J. Glennie. 2002. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol. 168:2720.
42. Sun, Y., D. Peng, J. Lecanda, V. Schmitz, M. Barajas, C. Qian, and J. Prieto. 2000. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther. 7:1467.
43. Noguchi, M., K. Imaizumi, T. Kawabe, H. Wakayama, Y. Horio, Y. Sekido, T. Hara, N. Hashimoto, M. Takahashi, K. Shimokata, and Y. Hasegawa. 2001. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-γ gene into lung cancer. Cancer Gene Ther. 8:421.
44. Wright, K. L., L. C. White, A. Kelly, S. Beck, J. Trowsdale, and J. P. Ting. 1995. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J. Exp. Med. 181:1459.
45. van den Broek, M. E., D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. Melief, R. M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781.
46. Smyth, M. J., M. H. Kershaw, and J. A. Trapani. 1997. Xenospecific cytotoxic T lymphocytes: potent lysis in vitro and in vivo. Transplantation 63:1171.
47. Seki, N., A. D. Brooks, C. R. Carter, T. C. Back, E. M. Parsoneault, M. J. Smyth, R. H. Wiltrout, and T. J. Sayers. 2002. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168:3484.
48. Medema, J. P., J. de Jong, T. van Hall, C. J. Melief, and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1033.
49. Jakobson, E., G. Jonsson, P. Bjorck, and S. Paulie. 1998. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int. J. Cancer 77:849.
50. Cromme, F. V., J. Airey, M. T. Heemels, H. L. Ploegh, P. J. Keating, P. L. Stern, C. J. Meijer, and J. M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335.
51. Cromme, F. V., P. F. van Bommel, J. M. Walboomers, M. P. Gallee, P. L. Stern, P. Kenemans, T. J. Helmerhorst, M. J. Stukart, and C. J. Meijer. 1994. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br. J. Cancer 69:1176.
52. Bugajska, U., N. T. Georgopoulos, J. Southgate, P. W. Johnson, P. Graber, J. Gordon, P. J. Selby, and L. K. Trejdosiewicz. 2002. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J. Natl. Cancer Inst. 94:1381.
53. Ghamande, S., B. L. Hylander, E. Oflazoglu, S. Lele, W. Fanslow, and E. A. Repasky. 2001. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 61:7556.
54. Vonderheide, R. H., J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, et al. 2001. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19:3280.
55. + CTL. J. Immunol. 164:4941.
56. Yang, S., and F. G. Haluska. 2004. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J. Immunol. 172:4599.
57. Correale, P., A. Aquino, A. Giuliani, M. Pellegrini, L. Micheli, M. G. Cusi, C. Nencini, R. Petrioli, S. P. Prete, L. De Vecchis, et al. 2003. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int. J. Cancer 104:437.